Long-acting antiretrovirals: a new era for the management and prevention of HIV infection
The long-acting antiretroviral cabotegravir and rilpivirine combination has just received FDA,
EMA and Health Canada approval. This novel drug delivery approach is about to …
EMA and Health Canada approval. This novel drug delivery approach is about to …
Long-acting antiretrovirals and HIV treatment adherence
Intramuscular injection of long-acting cabotegravir and rilpivirine is a novel, long-acting
antiretroviral therapy (ART) combination approved for use as a fully suppressive regimen for …
antiretroviral therapy (ART) combination approved for use as a fully suppressive regimen for …
Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research
Introduction Despite significant advances in treatment and prevention of HIV-1 infection,
poor adherence to daily combination antiretroviral therapy (ART) regimens remains a major …
poor adherence to daily combination antiretroviral therapy (ART) regimens remains a major …
Ethical issues in therapeutic use and research in pregnant and breastfeeding women
Pregnant or potentially pregnant women have historically been excluded from clinical trials
of new medications. However, it is increasingly recognised that it is imperative to generate …
of new medications. However, it is increasingly recognised that it is imperative to generate …
Development of long-acting injectable suspensions by continuous antisolvent crystallization: An integrated bottom-up process
Our present work elucidated the operational feasibility of direct generation and stabilization
of long-acting injectable (LAI) suspensions of a practically insoluble drug, itraconazole (ITZ) …
of long-acting injectable (LAI) suspensions of a practically insoluble drug, itraconazole (ITZ) …
Impact of long-acting therapies on the global HIV epidemic
Long-acting antiretroviral drugs have emerged as exciting treatment and preexposure
prophylaxis (PrEP) options for people with HIV and at risk of HIV. Long-acting regimens may …
prophylaxis (PrEP) options for people with HIV and at risk of HIV. Long-acting regimens may …
Factors associated with preferences for long-acting injectable antiretroviral therapy among adolescents and young people living with HIV in South Africa
Long-acting injectable anti-retroviral therapy (LAART) may overcome barriers to long-term
adherence and improve the survival of adolescents and young people living with HIV …
adherence and improve the survival of adolescents and young people living with HIV …
Impact of excipients and seeding on the solid-state form transformation of indomethacin during liquid Antisolvent precipitation
M Hugo Silva, A Kumar, BK Hodnett… - Crystal growth & …, 2022 - ACS Publications
Long-acting injectables are a unique drug formulation strategy, providing a slow and
sustained release of active pharmaceutical ingredients (APIs). In this study, a novel …
sustained release of active pharmaceutical ingredients (APIs). In this study, a novel …
Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list
M Penazzato, CL Townsend, N Rakhmanina… - The Lancet …, 2019 - thelancet.com
Despite considerable progress in paediatric HIV treatment and timely revision of global
policies recommending the use of more effective and tolerable antiretroviral regimens …
policies recommending the use of more effective and tolerable antiretroviral regimens …
The future of long-acting agents for preexposure prophylaxis
C Flexner - Current Opinion in HIV and AIDS, 2022 - journals.lww.com
Long-acting antiretroviral products have substantial promise for PrEP and have particular
advantages over daily oral drugs based mainly on improved adherence. However, there are …
advantages over daily oral drugs based mainly on improved adherence. However, there are …